This bulletin presents the latest figures from the Office for National Statistics (ONS) on deaths related to drug poisoning (involving both legal and illegal drugs) and drug misuse (involving illegal drugs) in England and Wales for the period 2006 to 2010. Figures are presented by cause of death, sex, age and substance(s) involved in the death.
Drug use and drug dependence are known causes of premature mortality, with drug poisoning accounting for nearly one in seven deaths among people in their twenties in 2010 (see Background Note 4). Consequently, there is considerable political, media and public interest in these figures.
Drug-related deaths occur in a variety of circumstances, each with different social and policy implications. This bulletin covers accidents and suicides involving drug poisonings, as well as deaths from drug abuse and drug dependence, but not other adverse effects of drugs (for example anaphylactic shock). Drug poisoning deaths involve a broad spectrum of substances, including legal and illegal drugs, prescription drugs (either prescribed to the deceased or obtained by other means) and over-the-counter medications. Some of these deaths may also be the result of complications of drug abuse, such as deep vein thrombosis or septicaemia resulting from intravenous drug use, or heart disease due to chronic cocaine use, rather than an acute drug overdose.
The previous government was in power during the majority of the period covered by this report. Therefore both current and previous policies are relevant to these data. The 2008 drug strategy of the previous government (Home Office, 2008) underpinned two Public Service Agreement (PSA) targets. PSA 25 aimed to reduce the harm caused by alcohol and drugs (including deaths) and PSA 14 aimed to increase the number of children and young people on the path to success.
In December 2010 the coalition government launched a new drug strategy entitled 'Reducing demand, restricting supply, building recovery: supporting people to live a drug-free life' (Home Office, 2010a). This strategy highlights preventing drug-related deaths as one of the key outcomes that services should be focused on.
Patterns of drug use change over time. For instance, in recent years people have been taking new psychoactive substances, including so-called ‘legal highs’ and precursor chemicals. In response to this, the 2010 drug strategy outlined the government’s plan to introduce a system of temporary 12-month bans on newly emerging substances. The Advisory Council on the Misuse of Drugs (ACMD) can then evaluate the harm caused by the substance and advise whether it should be permanently banned.
The figures contained in this statistical bulletin are used by a range of public bodies, such as the National Treatment Agency for Substance Misuse (NTA) and the Department of Health (DH), to evaluate the effectiveness of drug strategies. The ACMD could also use these figures to help evaluate the risk of death posed by new psychoactive substances. However, results should be treated with caution as it may not be possible to identify new substances during post-mortem investigations. It is also important to note that this statistical bulletin cannot shed any light on other types of short-term harm associated with drug use (for example, social or psychological) or the long-term damage that using such substances may cause.
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) combines data from the England and Wales drug poisoning database with data from Scotland and Northern Ireland to create UK figures which allow international comparisons with other European countries. The latest EMCDDA report shows that the drug-related death rate in the UK was higher than most other European countries (EMCDDA, 2011). However, the authors advise caution when making international comparisons, because of differences in definitions and the quality of reporting.
Data from the drug poisoning database are also used by academics and other researchers. For example, researchers from Centre for Suicide Research at the University of Oxford analysed ONS drug-related deaths data and concluded that there was a major reduction in deaths involving co-proxamol following its withdrawal in 2005, with no evidence of an increase in deaths involving other analgesics (Hawton et al, 2009). Updated data on deaths involving co-proxamol are shown below in Table 3.
There were 2,747 deaths from drug poisoning (involving both legal and illegal drugs) in 2010, and as in previous years, the majority (nearly 70 per cent) of these deaths were in males. There were 1,890 male deaths from drug poisoning in 2010, a decrease of 10 per cent since 2009. The equivalent number of female deaths rose to 857, an increase of 10 per cent since 2009 and the highest number since 2005 (figures from 1993 onwards are available on the ONS website (79.5 Kb Excel sheet) ).
|England and Wales||Deaths|
|All drug poisoning||Males||1,782||1,914||2,075||2,098||1,890|
In line with previous years, in 2010 the largest proportion (48 per cent) of drug poisoning deaths in males were from ‘accidental poisoning by drugs’, but in females the largest proportion (46 per cent) were from ‘intentional self-poisoning and poisoning of undetermined intent’ (suicides). Over the past few years relatively fewer deaths have been assigned an underlying cause of mental and behavioural disorders (drug abuse and drug dependence) and an increasing number of deaths have been due to accidental poisonings. The reasons for this trend are not clear.
|England and Wales||Deaths|
|Mental and behavioural disorders due to drug use (excluding alcohol and tobacco) (F11–F16, F18–F19)||Males||639||662||705||586||504|
|Accidental poisoning by drugs, medicaments and biological substances (X40–X44)||Males||598||725||861||983||899|
|Intentional self-poisoning by drugs, medicaments and biological substances (X60-X64), and poisoning by drugs, medicaments and biological substances, undetermined intent (Y10–Y14)||Males||540||520||500||524||482|
|Assault by drugs, medicaments and biological substances (X85)||Males||5||7||9||5||5|
The definition of this indicator is '(a) deaths where the underlying cause is drug abuse or drug dependence or (b) deaths where the underlying cause is drug poisoning and where any of the substances controlled under the Misuse of Drugs Act 1971 are involved'. This definition has been adopted across the UK.
Overall in 2010, there were 1,784 drug misuse deaths. The number of male deaths decreased by 9 per cent from 1,512 in 2009 to 1,382 in 2010. However over the same period the number of female deaths rose by 10 per cent to 402 (Table 1).
Compared with 2006, in 2010 a higher proportion of drug poisoning deaths were related to drug misuse. However since 2007 this proportion has remained fairly static at 73 per cent for males and 47 per cent for females.
The male death rate for all drug related poisonings fell significantly between 2009 and 2010, from 76.7 to 68.8 deaths per million population (Figure 1). Over the same period the male rate for deaths related to drug misuse dropped slightly, but not significantly, to 50.8 deaths per million population. The female death rates for all drug related poisonings and for deaths from drug misuse both increased slightly, but not significantly, between 2009 and 2010 (29.2 and 14.0 deaths per million population respectively in 2010).
Figure 2 shows that males aged 20 to 49 have the highest mortality rates from drug misuse, markedly higher than the rates for males in other age groups and much higher than females of any age. Within this broad age range the highest male mortality rate was among males aged 30 to 39, throughout the period 2006 to 2010. Moreover, these rates have been gradually increasing since 2006, and were significantly higher in 2010 compared with 2006 (150.8 deaths per million population in 2010). In contrast, rates among males aged 20 to 29 have declined significantly over this period.
Although mortality rates for deaths related to drug misuse in males aged 50 to 69 were comparatively lower, they increased significantly between 2006 and 2010. In 2010 the lowest rate for males was in the under 20 age group (3.6 deaths per million population); and rates were also low in males aged 70 and over. The mortality rates in the oldest and youngest age groups showed no significant trends between 2006 and 2010.
In 2010, mortality rates from drug misuse rates for females were lower than males in every age group. As with males, the highest rate was among those aged 30 to 39 (29.2 deaths per million population) and the lowest rate was in those under 20 (1.7 deaths per million population). Rates in younger females (under 30) have tended to decrease slightly over this period, where as in females aged 30 and over, rates have increased slightly. However, the only significant trend was in females aged 40 to 49, where rates were significantly higher in 2010 compared with 2006 (but not as high as the peak in 2008).
Figure 3 gives the age-standardised death rates where selected substances were mentioned on the death certificate for 2006 to 2010 and Table 3 gives the number of deaths from a wide range of substances. These figures need to be interpreted with caution for the following reasons:
These figures are based on information reported on the coroner’s death certificate, and may not include all substances involved in the death
In around 12 per cent of drug poisoning deaths only a general description is recorded on the coroner’s certificate of death (such as drug overdose or multiple drug toxicity). These deaths do not contribute to the count of specific substances
In an additional 30 per cent of all drug poisoning deaths, the death certificate mentions more than one specific drug. Where more than one drug is mentioned, it is not always possible to tell which of them was primarily responsible for the death
Where more than one drug is mentioned on a death certificate the death will be counted in more than one category in Table 3. For example, if both heroin and cannabis are mentioned, the death will be recorded once under heroin and once under cannabis. Therefore the numbers for different substances cannot be added together to give a total number of deaths
Approximately a third of all drug-related poisoning deaths also contain a mention of alcohol or long-term alcohol abuse (for example cirrhosis) in addition to a drug
Over half (58 per cent) of all deaths related to drug poisoning involved an opiate drug. In 2010 there were 791 deaths involving the opiates heroin and/or morphine (see Background Note 5). For males, heroin/morphine was involved in far more deaths than any other substance. Between 2009 and 2010 there was a small, but non-significant, drop in the age-standardised mortality rate for males (24.6 deaths per million population). The corresponding rate in females was much lower at 4.5 deaths per million population, and has not changed significantly over the five-year period.
A large number of deaths involved the opiate methadone, a substance used to treat heroin addiction, but which is sometimes abused. In 2010 there were 355 deaths involving methadone. The male age-standardised rate for deaths involving methadone fell slightly to 9.9 deaths per million population in 2010, but it was still significantly higher than the rate in 2006 (7.2 deaths per million population). The equivalent rate for females remained stable in 2010 at 3.2 deaths per million population.
There were 144 deaths involving cocaine in 2010. Between 2009 and 2010 male mortality rates for deaths involving cocaine decreased significantly from 6.6 to 4.6 deaths per million population (a 30 per cent fall). The equivalent rates for females were lower than for males, falling slightly from 0.9 in 2009 to 0.7 deaths per million population in 2010.
The number of deaths involving amphetamine fell to 56 in 2010. Most notably the number of deaths involving ecstasy has declined each year from 2006 to 2010, falling sharply to only eight deaths in 2010 (a fall of 70 per cent compared with 2009).
Over the past few years a number of new drugs have been controlled under the Misuse of Drugs Act 1971, including synthetic cannabinoid receptor agonists (for example, ‘spice’), gamma-hydroxybutyrate (GHB) and its precursor gamma-butyrolactone (GBL), piperazines (benzyl piperazine – BZP and trifluoromethylphenylpiperazine – TFMPP) and most recently mephedrone. There were six deaths involving mephedrone in 2010, the first time this substance had been mentioned on death certificates in England and Wales. The number of deaths involving other so-called ‘legal highs’ have fallen slightly in 2010, and are low relative to the number of deaths from heroin/morphine.
According to results from the British Crime Survey the proportion of 16- to 59-year-olds reporting cocaine use in 2009/10 was significantly lower than 2008/09, but was similar to previous years (Home Office, 2010b). The Druglink Street Drug Trends Survey 2010 suggested that due to the current harsh economic climate people are only buying small amounts of cocaine (Daly, 2010). Moreover, there is evidence that the purity of cocaine is decreasing (Daly, 2009). It has also been reported that fewer people are taking ecstasy due to its poor quality (Daly, 2010). Academics from Cambridge University and other experts have suggested that people may have switched from using cocaine and ecstasy to using ‘legal highs’ such as mephedrone (Bird and Mercer, 2011 and Davies et al, 2010). This may partially explain the fall in deaths from cocaine and ecstasy, and the emergence of deaths involving mephedrone. It is interesting to note that the number of deaths from mephedrone is not as large as the corresponding fall in cocaine and ecstasy deaths.
There were 307 drug poisoning deaths involving benzodiazepines in 2010. Mortality rates were higher in males than in females and have increased in both sexes over the period from 2006 to 2010. In males the rate increased from 4.5 to 7.8 deaths per million population (a 73 per cent rise); and in females the rate rose from 1.7 to 3.1 deaths per million (an 82 per cent increase). The most common type of benzodiazepine involved in deaths was diazepam, with the number of deaths more than doubling from 89 in 2006 to 186 in 2010.
A recent survey suggests that ‘black market’ diazepam use continues to rise (Daly, 2010), which may explain the increase in deaths. However, the role of diazepam and other benzodiazepines in drug-related deaths is not clear, as 9 out of 10 deaths involving benzodiazepines also mention another drug.
There were 381 deaths involving antidepressants in 2010. Death rates were similar in males and females in 2010 (6.8 and 6.7 deaths per million population respectively), and have not changed significantly over the past five years. Compared with other types of antidepressants, more deaths involve tricyclic antidepressants (TCAs), but deaths involving TCAs are declining and reached a record low of 194 deaths in 2010. However, deaths involving Selective Serotonin Re-uptake Inhibitors (SSRIs) have been steadily increasing, and reached a record high of 136 deaths in 2010. In particular, deaths involving the SSRI citalopram have more than doubled in the last five years, from 46 deaths in 2006 to 96 deaths in 2010. Studies show that SSRIs are less toxic in overdose than TCAs (Hawton et al, 2010), hence the rise in SSRI-related deaths may be explained by increases in SSRI prescriptions. Hawton et al (2010) also suggests that citalopram is more toxic in overdose than other SSRIs, which has implications for prescribing practices.
Deaths involving paracetamol and its compounds continued to fall, with 199 deaths in 2010. The male mortality rate for these deaths fell by 39 per cent between 2009 and 2010, from 4.9 to 3.0 deaths per million population. In females, the equivalent rate went down between 2006 and 2007 and has remained relatively stable since then. In 2010 the female mortality rate was similar to that for males, at 3.4 deaths per million population.
The decline in deaths involving paracetamol is largely because of a fall in deaths mentioning co-proxamol (paracetamol and dextropropoxyphene), which fell by 87 per cent between 2006 and 2010. This can be explained by the withdrawal of co-proxamol in 2005 (Hawton et al, 2009). Despite the decrease in deaths involving co-proxamol Hawton et al (2009) suggested that there was no statistical evidence for an increase in deaths involving other analgesics. The latest data for deaths mentioning co-codamol (paracetamol and codeine), co-dydramol (paracetamol and dihydrocodeine), dihydrocodeine not from a compound and paracetamol not from a compound appear to support this, since the numbers of deaths have all either fallen or remained relatively stable over the past five years.
However, the number of deaths mentioning either codeine and/or tramadol (a synthetic opioid analgesic) have increased in recent years. The number of deaths involving tramadol have been steadily increasing since 1993 (when ONS records began), with deaths showing a marked rise from 87 in 2009 to 132 in 2010 (an increase of 52 per cent). At present, unlike most other opioid analgesics, tramadol is not controlled under the Misuse of Drugs Act 1971. The number of deaths mentioning codeine (not from a compound formulation) increased by 50 per cent between 2006 and 2009, and stabilised in 2010 when there were 91 deaths. It is not clear from these figures whether the increase in deaths from codeine and tramadol is in people who have been prescribed these drugs or in people who are using them recreationally.
In 2006 there were only two deaths involving helium, and in 2010 there were 33. Although the number of deaths involving helium is small compared with many other substances, this rise is the largest percentage increase in deaths mentioning a specific substance between 2006 and 2010. This may be of particular interest to suicide prevention researchers, as most deaths mentioning helium were suicides. See Background Note 8 for further information on helium deaths.
|England and Wales||Deaths|
|All drug poisonings||2,570||2,640||2,928||2,878||2,747|
|Heroin / Morphine||713||829||897||880||791|
|Gamma-hydroxybutyrate (GHB) / Gamma-butyrolactone (GBL)||7||9||20||16||12|
|BZP / TFMPP||0||0||0||9||5|
|Zopiclone / Zolpidem||39||51||36||79||67|
|Tricyclic antidepressants (BNF 4.3.1)||212||203||227||218||194|
|Selective serotonin re-uptake inhibitors (BNF 4.3.3)||76||80||116||113||136|
|Other antidepressants (BNF 4.3.2 and 4.3.4)||46||63||49||81||71|
|Antipsychotics (BNF 4.2.1)||78||82||87||83||87|
|Paracetamol (includes dextropropoxyphene mentioned without paracetamol)3||309||242||260||255||199|
|Paracetamol & dextropropoxyphene compound formulation3||97||72||48||32||13|
|Paracetamol & codeine compound formulation||42||49||57||53||43|
|Paracetamol & dihydrocodeine compound formulation||18||9||12||13||4|
|Paracetamol not from compound formulation||154||115||147||160||139|
|Codeine not from compound formulation5||60||60||70||90||91|
|Dihydrocodeine not from compound formulation||96||85||79||99||90|
|Figures are for deaths registered in each calendar year.|
A back series of data on deaths related to drug poisoning in England and Wales between 1993 and 2010 are available to download in a Microsoft Excel workbook from the ONS website (79.5 Kb Excel sheet) . The workbook contains the following tables:
Table 1 – Numbers of deaths from drug-related poisoning and drug misuse: by sex
Table 2a – Numbers of deaths from drug-related poisoning: by sex and underlying cause of death
Table 2b – Numbers of deaths from drug-related poisoning: by sex and age group
Table 3a – Numbers of deaths from drug misuse: by sex and underlying cause of death
Table 3b – Numbers of deaths from drug misuse: by sex and age group
Table 4a,b,c – Numbers of deaths where selected substances were mentioned on the death certificate (total mentions, mentions alone and mentions with alcohol)
Table 5 – Number of deaths related to drug misuse: by sex and country
The Advisory Council on the Misuse of Drugs (2000) Reducing drug related deaths, Home Office: London.
Bird S and Mercer P (2011) 'Mephedrone and cocaine: clues from Army testing', Straight Statistics Website, accessed on 20 July 2011 at: www.straightstatistics.org/article/mephedrone-and-cocaine-clues-army-testing
Christophersen O, Rooney C and Kelly S (1998) ‘Drug related deaths: methods and trends’, Population Trends 93, 29–37.
Daly M (2009) ‘Dealers rely on cutting agents as cocaine purity hits all time low’, Druglink May/June 2009, 3.
Daly M (2010) ‘Booze, bans and bite-size bags’, Druglink September/October 2010, 6-9.
Davies C, English L, Lodwick A, McVeigh J and Bellis M A (2010) ‘United Kingdom drug situation: annual report to the European Monitoring
Centre for Drugs and Drug Addiction (EMCDDA) 2010’, accessed on 29 June 2011 at: www.nwph.net/ukfocalpoint
Department of Health (2001) The Government Response to the Advisory Council on the Misuse of Drugs Report into Drug Related Deaths, Department of Health: London.
The European Monitoring Centre for Drugs and Drug Addiction (2011) ‘Statistical Bulletin: Drug-related deaths and mortality’, accessed on 18 July 2011 at: www.emcdda.europa.eu/stats11/drd
Hawton K, Bergen H, Simkin S, Brock A, Griffiths C, Romeri E, Smith K L, Kapur N and Gunnell D (2009) ‘Effect of withdrawal of co-proxamol on prescribing and deaths from drug poisoning in England and Wales: time series analysis’ British Medical Journal, 338.
Hawton K, Bergen H, Simkin S, Cooper J, Waters K, Gunnell D and N Kapur (2010) ‘Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose’, The British Journal of Psychiatry 196, 354-358.
Home Office (2008) ‘Drugs: protecting families and communities – The 2008 drug strategy’. Accessed on 15 July 2011 at: http://webarchive.nationalarchives.gov.uk/20100419081707/http:/drugs.homeoffice.gov.uk/publication-search/drug-strategy/drug-strategy-2008
Home Office (2010a) ‘Drug Strategy 2010 – Reducing demand, restricting supply, building recovery: supporting people to live a drug-free life'. Accessed on 15 July 2011 at: www.homeoffice.gov.uk/publications/alcohol-drugs/drugs/drug-strategy/drug-strategy-2010
Home Office (2010b) ‘Drug Misuse Declared: Findings from the 2009/10 British Crime Survey England and Wales’ Accessed on 17 August at: http://webarchive.nationalarchives.gov.uk/+/http:/www.homeoffice.gov.uk/publications/science-research-statistics/research-statistics/drugs-alcohol- research/hosb1310/?view=Standard&pubID=865142
The Misuse of Drugs Act (1971) The Stationary Office Ltd, accessed on 17 August 2011 at: www.legislation.gov.uk/ukpga/1971/38/contents
Office for National Statistics (2002) ‘Report: Deaths related to drug poisoning: results for England and Wales, 1993 to 2000’, Health Statistics Quarterly 13, 76–82. Available at: www.ons.gov.uk/ons/rel/hsq/health-statistics-quarterly/no--13--spring-2002/index.html
The figures presented in this bulletin have been produced using a special database of deaths related to drug poisoning, which has been developed to facilitate research into these deaths and to aid the identification of specific substances involved. The database is extracted from the national mortality database for England and Wales. Deaths are included if the underlying cause of death is regarded as drug-related, according to the National Statistics definition. More information on this definition and issues relating to the interpretation of drug-related deaths data can be found in Christophersen et al (1998). The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) codes used to define these deaths are listed below.
|F11-F16, F18-F19||Mental and behavioural disorders due to drug use (excluding alcohol and tobacco)|
|X40-X44||Accidental poisoning by drugs, medicaments and biological substances|
|X60-X64||Intentional self-poisoning by drugs, medicaments and biological substances|
|Y10-Y14||Poisoning by drugs, medicaments and biological substances, undetermined intent|
|X85||Assault by drugs, medicaments and biological substances|
Almost all deaths on the drug poisoning database had a coroner’s inquest. For each death the database includes the following information:
The ICD codes for underlying cause of death and other causes mentioned on the death certificate.
Every mention of a substance recorded by the coroner in the cause of death section or elsewhere on the coroner's certificate after inquest (Form 99(REV)).
An indicator to show if alcohol is mentioned. This includes a wide variety of scenarios ranging from evidence of alcohol consumption around the time of death (for example an empty vodka bottle found at the scene or alcohol found after toxicology tests) to long-term alcohol abuse and cirrhosis of the liver.
Other information recorded at death registration such as age, sex, marital status, occupation and place of usual residence.
In 2000 the Advisory Council on the Misuse of Drugs published a report, Reducing Drug Related Deaths (The Advisory Council on the Misuse of Drugs, 2000). In response to this report’s recommendations on improving the present system for collecting data on drug-related deaths, a technical working group was set up. This group, consisting of experts across government, the devolved administrations, coroners, toxicologists and drugs agencies, proposed a headline indicator for drug misuse deaths as part of the government’s action plan (Department of Health, 2001) to reduce the number of these deaths. This indicator also takes into account the information needs of the European Monitoring Centre for Drugs and Drug Addiction. The baseline year for monitoring deaths related to drug misuse was set as 1999. The definition of the headline indicator using ICD-10 is shown below. The definition using ICD 9 was published in a previous annual report (Office for National Statistics, 2002).
Definition of the headline indicator of drug misuse deaths
Cause of death categories included in the headline indicator of drug misuse deaths (the relevant ICD-10 codes are given in brackets):
a) Deaths where the underlying cause of death has been coded to the following categories of mental and behavioural disorders due to psychoactive substance use (excluding alcohol, tobacco and volatile solvents):
sedatives or hypnotics (F13)
other stimulants, including caffeine (F15)
multiple drug use and use of other psychoactive substances (F19)
b) Deaths coded to the following categories and where a drug controlled under the Misuse of Drugs Act 1971 was mentioned on the death record:
Accidental poisoning by drugs, medicaments and biological substances (X40–X44)
Intentional self-poisoning by drugs, medicaments and biological substances (X60–X64)
Poisoning by drugs, medicaments and biological substances, undetermined intent (Y10–Y14)
Assault by drugs, medicaments and biological substances (X85)
Mental and behavioural disorders due to use of volatile solvents (F18)
i. Specific rules were adopted for dealing with compound analgesics which contain relatively small quantities of drugs listed under the Misuse of Drugs Act, the major ones being dextropropoxyphene, dihydrocodeine and codeine. Where these drugs are mentioned on a death record, they have been excluded from the drug misuse indicator if they are part of a compound analgesic (such as co-proxamol, co-dydramol or co-codamol) or cold remedy. Dextropropoxyphene has been excluded on all occasions, whether or not paracetamol or a compound analgesic was mentioned. This is because dextropropoxyphene is rarely, if ever, available other than as part of a paracetamol compound. However, codeine or dihydrocodeine mentioned without paracetamol or ibuprofen were included in the indicator. This is because they are routinely available and known to be abused in this form. This approach is the same as that taken by National Records of Scotland (NRS).
ii. Drugs controlled under the Misuse of Drugs Act 1971 include class A, B and C drugs.
Nearly one in seven deaths among people in their twenties were drug-related. This figure has been calculated from the number of deaths from all drug poisonings of people aged 20-29, in England and Wales in 2010 (444 deaths) and the number of deaths from all causes in this age group in England and Wales in 2010 (3,281 deaths). The number of deaths from all causes, by sex and age is available on the ONS website (281.5 Kb Excel sheet) .
As heroin (diamorphine) breaks down in the body into morphine, either heroin and/or morphine may be detected at post mortem and recorded on the death certificate. Therefore a combined figure for deaths where heroin or morphine was mentioned on the death certificate is included in Table 3.
The figure for cocaine in Table 3 includes deaths where cocaine was taken in the form of crack cocaine. It is not possible to separately identify crack cocaine from other forms of cocaine at post mortem. Other evidence to distinguish the form of cocaine taken is rarely provided on death certificates.
The figure for GHB (gamma-hydroxybutyrate) in Table 3 includes deaths where GBL (gamma-butyrolactone) was taken. It is not possible to separately identify GBL and GHB at post mortem as GBL is rapidly converted to GHB when ingested into the human body.
The number of deaths mentioning helium reported in this statistical bulletin is likely to be an underestimate, as some deaths involving helium have an underlying cause of death of hanging, strangulation and suffocation (ICD-10 codes X70 and Y20), and are not included in the drug poisoning database.
Death rates presented in Figures 1 and 3 are deaths per million population, directly age-standardised to the European standard population.
Excel workbooks containing the data used to produce Figures 1 (33 Kb Excel sheet) , 2 (23.5 Kb Excel sheet) and 3 (31 Kb Excel sheet) are available to download from the ONS website. These tables contain both the mortality rate and the upper and lower confidence limits. These limits form a confidence interval, which is a measure of the statistical precision of an estimate and shows the range of uncertainty around the estimated figure. Calculations based on small numbers of events are often subject to random fluctuations. As a general rule, if the confidence interval around one figure overlaps with the interval around another, we cannot say with certainty that there is more than a chance difference between the two figures. Within this statistical bulletin, a difference which is described as ‘significant’, means ‘statistically significant’, assessed by examining the confidence intervals.
Special extracts and tabulations of drug poisoning deaths data are available to order for a charge (subject to legal frameworks, disclosure control and agreement of costs, where appropriate). Such requests or enquiries should be made to:
Mortality Analysis Team, Health and Life Events Division
Office for National Statistics
Gwent NP10 8XG
Tel: 01633 455341
As a valued user of our statistics, we would welcome feedback on this release. In particular, the content, format and structure. This is in line with the Health and Life Events user engagement strategy (95.1 Kb Pdf) , available to download from the ONS website.
Please send feedback to the postal or e-mail address above.
Details of the policy governing the release of new data are available from the Media Relations Office.
National Statistics are produced to high professional standards set out in the Code of Practice for Official Statistics. They undergo regular quality assurance reviews to ensure that they meet customer needs. They are produced free from any political interference.
© Crown copyright 2011.
You may re-use this information (not including logos) free of charge in any format or medium, under the terms of the Open Government Licence, or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU
National Statistics are produced to high professional standards set out in the Code of Practice for Official Statistics. They undergo regular quality assurance reviews to ensure that they meet customer needs. They are produced free from any political interference.
A list of the persons given 24 hours pre-release access to this release is available on the ONS wesbite (32.5 Kb Pdf) .
Next publication: August 2012
Issued by: Office for National Statistics, Government Buildings, Cardiff Road, Newport NP10 8XG
Tel: Media Relations Office 0845 6041858, Emergency on-call 07867 906553
Details of the policy governing the release of new data are available by visiting www.statisticsauthority.gov.uk/assessment/code-of-practice/index.html or from the Media Relations Office email: firstname.lastname@example.org
|Vanessa Fearn||+44 (0)1633 455341||Health and Life Events Divisionemail@example.com|